To further confirm whether our in vitro findings can be translated in vivo for clinically relevant anti-tumor treatment, we used RB-proficient TNBC patient-derived orthotopic xenograft (PDOX) and RB-deficient MDA-MB-468 xenograft mouse models to evaluate the anti-tumor efficacy of the two-drug regimen. The gene discussed is RB1; the disease is neoplasm.